A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia

Phase 3

Recruiting

• Conditions: Febrile Neutropenia
• Interventions: Drug: Fosfomycin Calcium

• Registration Number: NCT05311254
• Lead Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias

Brief Summary

Randomized phase 3 trial to compare efficacy and safety of oral fosfomycin versus ciprofloxacin to prevent febrile neutropenia in patients with acute leukemia or recipients of hematopoietic stem cell transplant.

Detailed Description

Multicenter, prospective, randomized, open label phase III trial to assess the efficacy and safety of oral fosfomycin vs. oral ciprofloxacin in the prevention of febrile neutropenia in patients with acute leukemia who are treated with intensive chemotherapy and/or are recipients of a hematopoietic stem cell transplant.

Non-inferiority design.

156 patients will be recruited: 78 in each arm

Study Timeline

• Study First Submitted: 2022-03-09
• Study Start: 2022-03-14
• Study First Submitted QC: 2022-04-04
• Study First Posted: 2022-04-05
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-12
• Last Update Posted: 2023-09-14
• Primary Completion: 2024-03-14
• Study Completion: 2024-03-14

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

1. Subjects who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure.

2. Adult subjects ≥ 18 years of age with acute leukemia diagnosis who are going to receive their first intensive chemotherapy cycle or adult subjects ≥ 18 years of age who are candidates to receive a first stem cell transplant.

3. Expected neutropenia 100x109/L lasting at least seven days. In case of expected neutropenia range 100-500x109/L lasting seven days or more, at least one of the following risk factors for infection must be present:

   1. Performance status (Eastern Cooperative Oncology Group, ECOG) ≥2.
   2. Expected mucositis grade 3-4.
   3. Age ≥65 years.
   4. Comorbidity Index (HCTI) ≥3.
   5. Serum albumin< 35 g/L.
   6. Total dose of etoposide > 500 mg/m2
   7. Total dose of cytarabine > 1 g/m2
   8. Active or refractory neoplasia at the moment of stem cell transplant.

4. Performance status (Eastern Cooperative Oncology Group, ECOG) of 0 to 3.

5. Adequate organ function defined as:

   Liver: bilirubin, alkaline phosphatase, or SGOT < 3 times the upper normal limit (unless it is attributable to tumor activity).

   Renal : creatinine ≤ 250 μmol/l (2.5 mg/dL) (unless it is attributable to AML activity).

6. Life expectancy higher than 3 months.

7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.

Exclusion Criteria

1. Hypersensitivity to fluoroquinolones or fosfomycin.
2. Treatment with broad spectrum antimicrobial therapy within 4 weeks of first study treatment.
3. Prior Intensive chemotherapy or stem cell transplant. Treatment with hydroxyurea or corticosteroids used to control white blood cell counts are permitted.
4. Fever of infectious origin or documented infection within 4 weeks of first study treatment.
5. Presence of any severe psychiatric disease or physical condition that, according to the physicians criteria, contraindicates the inclusion of the patient into the clinical trial.
6. Subjects that have participated previously in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ciprofloxacin	Fosfomycin Calcium	Oral ciprofloxacin, tablets containing 500 mg of active drug.
Fosfomycin	Fosfomycin Calcium	Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.

Primary Outcome Measures

Name	Time	Method
Febrile neutropenia of infectious origin	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Febrile neutropenia that requires antibacterial treatment.

Secondary Outcome Measures

Name	Time	Method
Use of broad spectrum antibiotics	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Index of days of antibiotics per hospitalization days. Antibiotics will be classified according the Watch/Reserve classification
Overall survival	Time from the day of randomization to the date of death, whatever the cause of death, up to 12 weeks.
Microbiome evolution	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Changes in the gut microbiome produced under both prophylactic strategies during the study period.
Microbiological safety	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Rate of patients colonized by multidrug resistant bacteria as determined by surveillance cultures
Documented infections	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Rate and type of documented infections
Drug related adverse events	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Incidence of Adverse Events (AE), severity and type of AEs.
Evolution of resistome	Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum	Rate of patients colonized by multidrug resistant bacteria as determined by metagenomic sequencing

Trial Locations

Locations (1)

Instituto de Investigación Sanitaria del Principado de Asturias; 🇪🇸 Oviedo, Asturias, Spain